UDK: 616.155.392.8-085 (470.45)

THE EFFECT OF THE TIME AND REGULARITY OF ADMINISTRATION OF IMATINIB MESYLATE (GLIVEK) ON SURVIVAL RATE

K. D. Kaplanov, T. Y. Klitochenko, E. G. Ovsyannikova, O. B. Kalashnikova, L. S. Tregubova, I. V. Matveeva, A. L. Shipaeva, E. G. Gemdgyan

Волгоградский областной клинический онкологический диспансер № 1, Гематологический научный центр РАМН, Москва

Abstract

The data on all the patients revealed in the city of Volgograd and Volgograd region from 1998 till 2009, suffering from the chronic myeloid leukemia, were processed and analyzed. 126 patients from the register were not treated with imatinib, and 103 patients started receiving imatinib at different times from the moment of diagnosis. We revealed the dependence of the survival rate on the timeliness of starting imatinib therapy after making diagnosis. Early onset of treatment (up to 4 months from the moment of diagnosis) has a reliable influence on uneventful survival and determines a tendency for overall survival improvement.

Keywords

chronic myeloid leukemia, imatinib (Glivec), overall survival, uneventful survival

Contacts

Капланов Камиль Даниялович — к. м. н., зав. отделением гематологии ГУЗ Волгоградский областной клинический онкологический диспансер № 1, e-mail: kamilos@mail.ru